Assessment of the efficacy of Lanreotide Autogel® in the reversal of sleep apnoea, left ventricular hypertrophy and hypertension when used as primary medical therapy in acromegaly

A comprehensive study of clinical, biochemical, radiological, cardiovascular and sleep parameters in an unselected cohort of patients with newly diagnosed ACROmegaly undergoing Pre-surgical somatostatin Analogue Therapy with Lanreotide Autogel® (ACROPAT)

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN20365485

Enrollment

Registered

2011-09-28

Start date

2004-03-01

Completion date

Unknown

Last updated

2018-02-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acromegaly and medical pre treatment with Lanreotide Autogel® Nutritional, Metabolic, Endocrine Acromegaly and pituitary gigantism

Interventions

Phase 1: Baseline assessments 1. Clinical Subjects will be asked to score various symptoms of acromegaly (e.g. headache, sweating, fatigue, arthralgia, carpal tunnel syndrome) using a 5-point scale (r

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Treatment naive newly diagnosed subjects with biochemically confirmed acromegaly 2. Males and females 3. More than 18 years of age

Exclusion criteria

Exclusion criteria: Subjects who had prior medical therapy, surgery or radiotherapy or sight-threatening tumours requiring urgent surgical decompression

Design outcomes

Secondary

Measure	Time frame
To determine the extent to which pre-surgical medical treatment with the SRL Lanreotide Autogel®: 1. Reduces GH and IGF1 levels 2. Reduces pituitary tumour volume 3. Corrects 'metabolic dysfunction' 4. Induces biliary 'sludge'/gallstone formation	—

Primary

Measure	Time frame
To determine the extent to which pre-surgical medical treatment with the SRL Lanreotide Autogel® ameliorates/reverses the following in newly diagnosed previously untreated acromegaly subjects: 1. Sleep disordered breathing 2. Cardiac hypertrophy and dysfunction 3. Hypertension and arterial dysfunction	—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026